INNOVITA disclosed its semi-annual report on the evening of August 28. In the first half of 2025, the company achieved operating revenue of 276 million yuan, a year-on-year decrease of 34.35%; the net profit attributable to shareholders of the listed company was 125 million yuan, a year-on-year decrease of 39.36%; basic earnings per share were 0.92 yuan. During the reporting period, the company's products faced challenges from a decline in the number of visits related to some hospitals and intensified industry competition; on the other hand, due to policy adjustments by relevant regulatory authorities, some of the company's products that originally applied the fiscal and tax [2014] No. 57 Article 2 "biological products that meet the requirements can choose to calculate and pay value-added tax at a rate of 3% using a simplified method" are no longer applicable and are now subject to a value-added tax at a rate of 13%, resulting in a year-on-year decline in the company's operating revenue of 34.35%, which also led to a simultaneous decline in related profit financial indicators and cash flow financial indicators